DK1334119T3 - Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet - Google Patents

Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet

Info

Publication number
DK1334119T3
DK1334119T3 DK01987765T DK01987765T DK1334119T3 DK 1334119 T3 DK1334119 T3 DK 1334119T3 DK 01987765 T DK01987765 T DK 01987765T DK 01987765 T DK01987765 T DK 01987765T DK 1334119 T3 DK1334119 T3 DK 1334119T3
Authority
DK
Denmark
Prior art keywords
motif
rsv infection
rsv
immunity
compositions
Prior art date
Application number
DK01987765T
Other languages
English (en)
Other versions
DK1334119T4 (da
Inventor
Ralph A Tripp
Les Jones
Larry J Anderson
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22911027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1334119(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of DK1334119T3 publication Critical patent/DK1334119T3/da
Application granted granted Critical
Publication of DK1334119T4 publication Critical patent/DK1334119T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01987765.3T 2000-10-18 2001-10-18 Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet DK1334119T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24152100P 2000-10-18 2000-10-18
PCT/US2001/032459 WO2002032942A2 (en) 2000-10-18 2001-10-18 Compositions and methods for modulating rsv infection and immunity

Publications (2)

Publication Number Publication Date
DK1334119T3 true DK1334119T3 (da) 2009-02-23
DK1334119T4 DK1334119T4 (da) 2019-03-18

Family

ID=22911027

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01987765.3T DK1334119T4 (da) 2000-10-18 2001-10-18 Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet

Country Status (9)

Country Link
US (4) US20040009177A1 (da)
EP (1) EP1334119B2 (da)
AT (1) ATE412666T1 (da)
AU (2) AU2002224416A1 (da)
CA (1) CA2426312C (da)
DE (1) DE60136381D1 (da)
DK (1) DK1334119T4 (da)
ES (1) ES2316487T5 (da)
WO (1) WO2002032942A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023029A2 (en) * 2004-06-16 2006-03-02 The Johns Hopkins University The cysteine-rich region of respiratory syncytial virus and methods of use therefor
AU2007222798A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
WO2008106980A2 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
AU2008316703B2 (en) 2007-10-25 2012-09-27 Trellis Bioscience, Inc. Anti-RSV G protein antibodies
GB0724253D0 (en) * 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
AU2009236585B2 (en) * 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
WO2011017442A2 (en) 2009-08-04 2011-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Anti-rsv immunogens and methods of immunization
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
GB0917792D0 (en) * 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
JP5890407B2 (ja) 2010-07-07 2016-03-22 アーティフィシャル セル テクノロジーズ インコーポレイテッド 呼吸器合胞体ウイルス抗原組成物および方法
CN103004009B (zh) * 2010-07-28 2015-11-25 日产自动车株式会社 双极型电极及使用它的双极型二次电池以及双极型电极的制造方法
CN109266622B (zh) 2012-08-01 2023-05-09 巴法里安诺迪克有限公司 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗
EP2993009A1 (de) * 2014-09-08 2016-03-09 HILTI Aktiengesellschaft Verfahren zur Steuerung eines Wandsägesystems beim Erstellen eines Trennschnittes
SE539731C2 (sv) 2016-03-04 2017-11-14 Vertical Wind Ab Rotor för en elektrisk generator och förfarande för dess tillverkning
JP7445895B2 (ja) * 2017-10-13 2024-03-08 トレリス・バイオサイエンス・インコーポレーテッド 呼吸器合胞体ウイルスｇタンパク質中央保存領域の立体構造エピトープ
US11201095B1 (en) 2019-08-23 2021-12-14 Xilinx, Inc. Chip package having a cover with window
AU2021241450A1 (en) * 2020-03-23 2022-09-15 Atossa Therapeutics, Inc. Heparin and N-acetylcysteine for the treatment of a respiratory virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2718452B1 (fr) † 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
CA2198279A1 (en) 1994-08-25 1996-02-29 Johannes Petrus Maria Langedijk Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection
AU1825097A (en) † 1996-01-24 1997-08-20 Schering Corporation Mammalian cx3c chemokine genes
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
EP1010692A1 (en) 1997-07-04 2000-06-21 Chisso Corporation Liquid-crystal compounds having large value of permittivity anisotropy, liquid-crystal composition containing the same, and liquid-crystal display element made using the liquid-crystal composition
KR100550132B1 (ko) 1997-09-19 2006-02-08 와이어쓰 홀딩스 코포레이션 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin

Also Published As

Publication number Publication date
AU2009200997B2 (en) 2011-12-22
US8173131B2 (en) 2012-05-08
DK1334119T4 (da) 2019-03-18
AU2009200997A1 (en) 2009-04-02
CA2426312A1 (en) 2002-04-25
WO2002032942A2 (en) 2002-04-25
ES2316487T3 (es) 2009-04-16
DE60136381D1 (de) 2008-12-11
AU2002224416A1 (en) 2002-04-29
EP1334119B2 (en) 2018-11-28
CA2426312C (en) 2014-01-14
US20040009177A1 (en) 2004-01-15
WO2002032942A3 (en) 2002-12-12
ES2316487T5 (es) 2019-05-13
US8778354B2 (en) 2014-07-15
US20060018925A1 (en) 2006-01-26
US20120258111A1 (en) 2012-10-11
EP1334119B1 (en) 2008-10-29
US20140288267A1 (en) 2014-09-25
ATE412666T1 (de) 2008-11-15
EP1334119A2 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
DK1334119T3 (da) Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
MY138860A (en) Hiv protease inhibitors.
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
DE60336550D1 (de) Inhibitoren des hepatitis-c-virus
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
DK1479691T3 (da) Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
DK1301201T3 (da) Behandling af glycogenosis type II
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
DK0517986T3 (da) Transformerede erythrocytter, fremgangsmåde til fremstilling af samme og deres anvendelse i farmaceutiske præparater
MXPA02007271A (es) Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales.
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
IS5956A (is) Notkun bisfosónsýra til varnar og meðhöndlunar sýkingaferla
WO2006109174A3 (en) Hiv vaccine comprising a glycoprotein 120 signal sequence with no more than one positively charged amino acid
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
EP1546415A4 (en) ANTI-TSG101 ANTIBODIES AND USES THEREOF FOR TREATING VIRAL INFECTIONS
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
EP1143981A4 (en) TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS
ATE237616T1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv
WO2003008410A3 (en) Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression
DK0470144T3 (da) D-Asparaginsyre-beta-hydroxamat til behandling af virale infektioner og tumorer